Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 11 mechanisms across 26 industry trials with a known mechanism of action.

See full pipeline →

Nonergot Dopamine Agonist

10 trials 4 sponsors

Catechol-O-Methyltransferase Inhibitor

4 trials 2 sponsors

Dopa-decarboxylase

2 trials 1 sponsor

Adenosine A2A receptor

2 trials 1 sponsor

Aromatic Amino Acid Decarboxylation Inhibitor

2 trials 2 sponsors

D2 receptor/D3 receptor/D4 receptor/D5 receptor/α1D receptor/α2B receptor/α2C receptor

1 trials 1 sponsor

Peroxisome Proliferator Receptor alpha Agonist

1 trials 1 sponsor

Iron Chelator

1 trials 1 sponsor

Cholinergic Nicotinic Agonist

1 trials 1 sponsor

Atypical Antipsychotic

1 trials 1 sponsor

Benzodiazepine

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

502 industry-sponsored trials across 197 sponsors

View full landscape →

Showing 27 of 27 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Impax Laboratories, LLC	CREXONT ER	—	RECRUITING	2025-11	NCT06765668
Bial - Portela C S.A.	Opicapone 50 mg	—	COMPLETED	2024-02-16	NCT04986982
Eisai Korea Inc.	Safinamide Mesilate	—	COMPLETED	2023-05-25	NCT05312632
Bial - Portela C S.A.	Opicapone	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2023-04-04	NCT04990284
Bial - Portela C S.A.	Opicapone	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2023-03-29	NCT04986995
SK Chemicals Co., Ltd.	Ongentys 50mg	—	COMPLETED	2022-08-18	NCT04821687
ACADIA Pharmaceuticals Inc.	Pimavanserin	—	COMPLETED	2022-04-26	NCT04292223
Zambon SpA	Safinamide Methanesulfonate	—	COMPLETED	2021-04-30	NCT03841604
Boehringer Ingelheim	Pramipexole SR	—	COMPLETED	2020-01-07	NCT03521635
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2018-07-04	NCT02847442
Novartis	pramipexole	—	COMPLETED	2016-05-23	NCT01673724
Teva Branded Pharmaceutical Products R&D, Inc.	Rasagiline	—	COMPLETED	2015-01	NCT01723228
GSK	ropinirole/L-dopa	—	COMPLETED	2014-11-18	NCT01494532
UCB Korea Co., Ltd.	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-10	NCT01523301
GSK	ropinirole monotherapy	—	COMPLETED	2014-04-30	NCT01485172
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals	APOKYN	—	COMPLETED	2014-04	NCT01770145
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-01	NCT01782222
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2013-12	NCT01744496
MedtronicNeuro	—	—	COMPLETED	2013-07	NCT00998660
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2013-03	NCT01711866
Teva Neuroscience, Inc.	Rasagiline	—	COMPLETED	2012-10	NCT01049984
UCB Pharma	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2012-10	NCT01300819
Lundbeck Italia S.p.A.	Rasagiline	—	COMPLETED	2012-07	NCT01055379
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals	APOKYN	—	TERMINATED	2016-12	NCT02549573
UCB Pharma SA	—	—	TERMINATED	2012-12	NCT01519882
Novartis	Carbidopa/levodopa/entacapone	—	TERMINATED	2009-05	NCT00642356
Novartis	carbidopa/levodopa	—	WITHDRAWN	2009-11	NCT00601978

Showing 100 of 109 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jiangsu HengRui Medicine Co., Ltd.	HRG2010; Sustained-release Carbidopa/Levodopa administered placebo	—	RECRUITING	2027-01-31	NCT06596876
BlueRock Therapeutics	bemdaneprocel	—	RECRUITING	2027-03	NCT06944522
Biohaven Therapeutics Ltd.	BHV-8000	—	RECRUITING	2027-08	NCT06976268
Roche	Prasinezumab	—	RECRUITING	2029-06-30	NCT07174310
Annovis Bio Inc.	buntanetap/posiphen	—	RECRUITING	2029-09	NCT07284784
Cerevance	CVN424 75 mg	—	ACTIVE NOT RECRUITING	2026-08	NCT06553027
AbbVie	ABBV-951	—	ACTIVE NOT RECRUITING	2026-04	NCT04750226
NeuroDerm Ltd.	Oral IR-LD/CD	—	ACTIVE NOT RECRUITING	2022-11-01	NCT04006210
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals	apomorphine infusion	—	ACTIVE NOT RECRUITING	2018-12	NCT02339064
AbbVie	ABBV-951	—	COMPLETED	2026-04-17	NCT04379050
Tasly Pharmaceutical Group Co., Ltd	pimavanserin tartrate	—	COMPLETED	2026-02-01	NCT06068465
AbbVie	Tavapadon	—	COMPLETED	2025-12-01	NCT04760769
AbbVie	Tavapadon	—	COMPLETED	2024-10-01	NCT04223193
GE Healthcare	SPECT	—	COMPLETED	2024-08-02	NCT04265209
AbbVie	Tavapadon	—	COMPLETED	2024-06-28	NCT04201093
AbbVie	Tavapadon	—	COMPLETED	2024-01-29	NCT04542499
Annovis Bio Inc.	buntanetap/posiphen	—	COMPLETED	2023-12-04	NCT05357989
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2022-11-08	NCT02542696
AbbVie	ABBV-951	—	COMPLETED	2022-08-17	NCT03781167
Impax Laboratories, LLC	IPX203	—	COMPLETED	2022-03-21	NCT03877510
Luye Pharma Group Ltd.	LY03003(Rotigotine,extended-release microspheres)	—	COMPLETED	2022-03-17	NCT04571164
GE Healthcare	DaTSCAN™ Ioflupane (123I) Injection	—	COMPLETED	2021-12-20	NCT04193527
AbbVie	Levodopa-Carbidopa Intestinal Gel (LCIG)	—	COMPLETED	2021-11-30	NCT00660673
AbbVie	ABBV-951	—	COMPLETED	2021-09-29	NCT04380142
Pharma Two B Ltd.	P2B001 0.6/0.75 mg	—	COMPLETED	2021-08-23	NCT03329508
Zambon SpA	Safinamide	—	COMPLETED	2021-08-20	NCT03881371
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2021-08-11	NCT03391882
Impax Laboratories, LLC	IR CD-LD	—	COMPLETED	2021-06-15	NCT03670953
AbbVie	Optimized Medical Treatment	—	COMPLETED	2020-05-14	NCT02549092
AbbVie	ABT-SLV187	—	COMPLETED	2019-10-31	NCT02082249
AbbVie	Optimized antiparkinsonian treatment	—	COMPLETED	2019-09-19	NCT02799381
Acorda Therapeutics	CVT-301	—	COMPLETED	2018-05	NCT02242487
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2018-02	NCT02202551
Kyowa Kirin Co., Ltd.	Istradefylline 20 mg or 40 mg	—	COMPLETED	2017-12-20	NCT02610231
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2017-12-11	NCT02469090
Acorda Therapeutics	CVT-301	—	COMPLETED	2017-05	NCT02352363
Takeda	TVP-1012 1mg	—	COMPLETED	2017-03-14	NCT02337751
Acorda Therapeutics	CVT-301 Low Dose	—	COMPLETED	2016-12	NCT02240030
Kyowa Kirin Co., Ltd.	Istradefylline 40 mg	—	COMPLETED	2016-10	NCT01968031
Takeda	TVP-1012 1mg	—	COMPLETED	2016-09-29	NCT02337764
Takeda	TVP-1012 1mg	—	COMPLETED	2016-09-17	NCT02337738
Takeda	TVP-1012	—	COMPLETED	2016-09-15	NCT02337725
Britannia Pharmaceuticals Ltd.	Apomorphine hydrochloride	D2 receptor/D3 receptor/D4 receptor/D5 receptor/α1D receptor/α2B receptor/α2C receptor	COMPLETED	2016-06-06	NCT02006121
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2016-03-10	NCT02274766
Avid Radiopharmaceuticals	18F-AV-133	—	COMPLETED	2016-03	NCT01550484
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2015-12	NCT02136914
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (100 Units)	—	COMPLETED	2015-08	NCT02091739
Pharma Two B Ltd.	P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),	—	COMPLETED	2015-05	NCT01968460
AbbVie (prior sponsor, Abbott)	Levodopa-Carbidopa Intestinal Gel	—	COMPLETED	2015-03	NCT01736176
AbbVie	Levodopa-carbidopa intestinal gel	—	COMPLETED	2015-03	NCT01960842
UCB Pharma	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-10	NCT01646255
UCB Pharma	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-05	NCT01646268
H. Lundbeck A/S	rasagiline	—	COMPLETED	2013-12	NCT01556165
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2013-11	NCT01568073
Mundipharma Research GmbH & Co KG	Oxycodone/Naloxone Prolonged Release tablets	—	COMPLETED	2013-08	NCT01439100
H. Lundbeck A/S	Azilect®	—	COMPLETED	2013-06	NCT01479530
Adamas Pharmaceuticals, Inc.	ADS-5102 (extended release amantadine HCl)	—	COMPLETED	2013-05	NCT01397422
Merck	Preladenant	—	COMPLETED	2013-04-04	NCT01227265
Impax Laboratories, LLC	IPX066	—	COMPLETED	2013-03	NCT01411137
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2013-03	NCT01723904
Merck	Preladenant 2 mg tablet	—	COMPLETED	2012-12-20	NCT01155466
ACADIA Pharmaceuticals Inc.	pimavanserin tartrate	—	COMPLETED	2012-11	NCT01174004
Biotie Therapies Inc.	Tozadenant (SYN115) 60 mg BID	—	COMPLETED	2012-10	NCT01283594
AbbVie (prior sponsor, Abbott)	Levodopa-carbidopa intestinal gel	—	COMPLETED	2012-10	NCT00360568
Chelsea Therapeutics	Droxidopa	Dopa-decarboxylase	COMPLETED	2012-10	NCT01176240
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2012-07	NCT01227655
AbbVie (prior sponsor, Abbott)	Levodopa-carbidopa intestinal gel	—	COMPLETED	2012-06	NCT00335153
Otsuka Pharmaceutical Co., Ltd.	SPM 962	—	COMPLETED	2012-06	NCT01631825
H. Lundbeck A/S	Azilect®	—	COMPLETED	2012-06	NCT01268891
GSK	Requip PR	—	COMPLETED	2012-03-01	NCT01536574
Impax Laboratories, LLC	IPX066	—	COMPLETED	2012-01	NCT01130493
Boehringer Ingelheim	pramipexole immediate release tablet	—	COMPLETED	2012-01	NCT01191944
Newron Pharmaceuticals SPA	Safinimide 50-100 mg/day	—	COMPLETED	2012-01	NCT00627640
Desitin Arzneimittel GmbH	piribedil	—	COMPLETED	2011-12	NCT01007864
Impax Laboratories, LLC	IPX066 95 mg	—	COMPLETED	2011-10	NCT01096186
AbbVie (prior sponsor, Abbott)	Levodopa carbidopa intestinal gel (LCIG)	—	COMPLETED	2011-10	NCT00660387
AbbVie (prior sponsor, Abbott)	Levodopa carbidopa intestinal gel (LCIG)	—	COMPLETED	2011-10	NCT00357994
GSK	ReQuip PR	—	COMPLETED	2011-09-01	NCT01154166
Kyowa Kirin Co., Ltd.	Istradefylline	Adenosine A2A receptor	COMPLETED	2011-09	NCT00957203
Kyowa Kirin Co., Ltd.	KW-6500	—	COMPLETED	2011-08	NCT01063621
Otsuka Pharmaceutical Co., Ltd.	SPM 962	—	COMPLETED	2011-05	NCT01628926
Catalysis SL	—	—	COMPLETED	2011-05	NCT01016470
Kyowa Kirin Co., Ltd.	Istradefylline	Adenosine A2A receptor	COMPLETED	2011-02	NCT00955526
Impax Laboratories, LLC	IPX066	—	COMPLETED	2011-01	NCT00974974
Kyowa Kirin Co., Ltd.	KW-6500	—	COMPLETED	2010-12	NCT00955318
GSK	ropinirole PR/XR	—	COMPLETED	2010-12	NCT00823836
Novartis	Rivastigmine capsule	—	COMPLETED	2010-11	NCT00623103
Impax Laboratories, LLC	IPX066 95 mg LD	—	COMPLETED	2010-10	NCT00880620
Kyowa Kirin Co., Ltd.	KW-6500	—	COMPLETED	2010-10	NCT01058291
Otsuka Pharmaceutical Co., Ltd.	SPM 962	—	COMPLETED	2010-10	NCT01628965
Boehringer Ingelheim	Pramipexole	—	COMPLETED	2010-06	NCT00601523
ACADIA Pharmaceuticals Inc.	Pimavanserin tartrate (ACP-103)	—	COMPLETED	2009-12	NCT00658567
Biogen	BIIB122	—	TERMINATED	2023-07-27	NCT05418673
Addex Pharma S.A.	Dipraglurant	—	TERMINATED	2022-06-17	NCT04857359
Addex Pharma S.A.	Dipraglurant	—	TERMINATED	2022-06-17	NCT05116813
Theravance Biopharma	ampreloxetine	—	TERMINATED	2021-11-10	NCT03829657
Biotie Therapies Inc.	Tozadenant	—	TERMINATED	2018-01-16	NCT03051607
Biotie Therapies Inc.	tozadenant	—	TERMINATED	2018-01-12	NCT02453386
Adamas Pharmaceuticals, Inc.	amantadine HCl ER	—	TERMINATED	2016-05-20	NCT02153632
Adamas Pharmaceuticals, Inc.	240mg Amantadine HCl ER tablets	—	TERMINATED	2016-05-20	NCT02153645

Showing 100 of 192 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Neuron23 Inc.	NEU-411	—	RECRUITING	2026-09	NCT06680830
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	18F-MFBG	—	RECRUITING	2026-09-30	NCT07176286
Hillhurst Biopharmaceuticals, Inc.	HBI-002	—	RECRUITING	2026-12-31	NCT07005180
Gateway Institute for Brain Research	INS-GSH	—	RECRUITING	2027-01-01	NCT05266417
GEN İlaç ve Sağlık Ürünleri A.Ş.	SUL-238 (1500 mg t.i.d.) film-coated tablets	—	RECRUITING	2027-03-01	NCT07322887
Integrative Research Laboratories AB	IRL757	—	RECRUITING	2027-05	NCT07461220
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	RECRUITING	2027-09	NCT07102342
Appello Pharmaceuticals, Inc.	AP-472	—	RECRUITING	2027-09-03	NCT07432958
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection	—	RECRUITING	2028-03-30	NCT07166757
AskBio Inc	AAV2-GDNF gene therapy	—	RECRUITING	2028-08-31	NCT06285643
Sumitomo Pharma America, Inc.	—	—	RECRUITING	2030-12-15	NCT06753331
Denali Therapeutics Inc.	BIIB122 225 mg	—	RECRUITING	2026-04-30	NCT06602193
Guangzhou Novaken Pharm Co., Ltd.	XJN010 Nasal Spray	—	RECRUITING	2026-03-30	NCT07156773
U: The Mind Company	—	—	RECRUITING	2026-03-01	NCT07182058
Ashvattha Therapeutics, Inc.	18F-OP-801	—	RECRUITING	2026-01-01	NCT05395624
Glaceum	Vutiglabridin	—	RECRUITING	2025-12-31	NCT06329141
Il-Yang Pharm. Co., Ltd.	Radotinib HCl 50 mg	—	RECRUITING	2025-12-31	NCT04691661
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	RECRUITING	2025-12	NCT06167681
Laboratorio Elea Phoenix S.A.	Cannabidiol 100 mg/ml	—	RECRUITING	2025-11	NCT06629389
Intra-Cellular Therapies, Inc.	Lenrispodun	—	RECRUITING	2025-09	NCT05766813
BioArctic AB	exidavnemab	—	ACTIVE NOT RECRUITING	2026-08-17	NCT06671938
Shanghai Vitalgen BioPharma Co., Ltd.	VGN-R09b	—	ACTIVE NOT RECRUITING	2026-09-10	NCT06480461
TrueBinding, Inc.	TB006	—	ACTIVE NOT RECRUITING	2026-11-28	NCT06773962
AC Immune SA	ACI-7104.056 at Dose A	—	ACTIVE NOT RECRUITING	2028-01	NCT06015841
MeiraGTx, LLC	—	—	ACTIVE NOT RECRUITING	2029-10	NCT05894343
Prevail Therapeutics	LY3884961	—	ACTIVE NOT RECRUITING	2030-12-31	NCT04127578
BioVie Inc.	NE3107	—	ACTIVE NOT RECRUITING	2026-05-01	NCT06757010
Bial R&D Investments, S.A.	BIA 28-6156 10 mg	—	ACTIVE NOT RECRUITING	2026-04-02	NCT05819359
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	ACTIVE NOT RECRUITING	2026-04	NCT06722729
Biogen	BIIB122	—	ACTIVE NOT RECRUITING	2026-02-25	NCT05348785
Chase Therapeutics Corporation	—	—	ACTIVE NOT RECRUITING	2025-12-30	NCT03683225
FAScinate Therapeutics Inc.	KM-819	—	ACTIVE NOT RECRUITING	2025-10-30	NCT05670782
BrainX Corporation	Ceftriaxone	—	ACTIVE NOT RECRUITING	2025-07-28	NCT03413384
Roche	Prasinezumab	—	ACTIVE NOT RECRUITING	2024-09-11	NCT04777331
Aptinyx	NYX-458	—	ACTIVE NOT RECRUITING	2022-12-30	NCT04148391
Roche	RO7046015	—	ACTIVE NOT RECRUITING	2019-11-27	NCT03100149
NeuroDerm Ltd.	ND0612	—	ACTIVE NOT RECRUITING	2019-09-09	NCT02726386
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	NOT YET RECRUITING	2026-12	NCT07028632
Shanghai Vitalgen BioPharma Co., Ltd.	VGN-R08b 4.2×10^13 vg	—	NOT YET RECRUITING	2027-09-01	NCT07414290
AskBio Inc	AB-1005	—	NOT YET RECRUITING	2027-12-30	NCT07215403
Qilu Pharmaceutical Co., Ltd.	GM1	—	NOT YET RECRUITING	2028-03	NCT07585565
Gain Therapeutics, Inc.	Low Dose GT-02287	—	NOT YET RECRUITING	2028-06-30	NCT07280299
Forest Hills Lab	Gemfibrozil	Peroxisome Proliferator Receptor alpha Agonist [EPC]	NOT YET RECRUITING	2028-11-01	NCT05931484
Biocells Medical	Intrathecal (IT)	—	NOT YET RECRUITING	2028-11-23	NCT07471230
Bayer	AB-1005	—	NOT YET RECRUITING	2028-12-15	NCT07566429
H. Lundbeck A/S	Lu AF28996	—	NOT YET RECRUITING	2028-12-30	NCT07514858
InnoMedica Schweiz AG	Talineuren	—	NOT YET RECRUITING	2025-11	NCT06431971
Mthera Pharma Co., Ltd.	MT101-5	—	NOT YET RECRUITING	2025-07	NCT06175767
S.Biomedics Co., Ltd.	Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose	—	COMPLETED	2025-12-10	NCT05887466
Hope Biosciences Research Foundation	Biological/Vaccine: Allogeneic HB-adMSCs	—	COMPLETED	2025-10-03	NCT04995081
Zomagen Biosciences Ltd.	VTX3232	—	COMPLETED	2025-04-04	NCT06556173
UCB Biopharma SRL	UCB0022	—	COMPLETED	2025-03-31	NCT06055985
Cerevance Beta, Inc.	CVN424 150 mg	—	COMPLETED	2025-01-30	NCT06006247
Celon Pharma SA	CPL500036 - low dose	—	COMPLETED	2025-01-13	NCT05297201
Integrative Research Laboratories AB	Pirepemat	—	COMPLETED	2024-12-04	NCT05258071
ABLi Therapeutics, Inc.	IkT-148009 (risvodetinib)	—	COMPLETED	2024-10-25	NCT05424276
Jazz Pharmaceuticals	Suvecaltamide	—	COMPLETED	2024-10-23	NCT05642442
UCB Biopharma SRL	UCB0599	—	COMPLETED	2024-09-06	NCT04658186
MeiraGTx, LLC	—	—	COMPLETED	2024-09-06	NCT05603312
SNLD, Ltd.	TR-012001	—	COMPLETED	2024-04-26	NCT06212089
Jiangsu HengRui Medicine Co., Ltd.	HRG2010(I)	—	COMPLETED	2024-01-31	NCT06614153
Supernus Pharmaceuticals, Inc.	SAGE-718	—	COMPLETED	2024-01-17	NCT05318937
Amydis Inc.	AMDX2011P	—	COMPLETED	2023-03-15	NCT05542576
Takeda	TAK-071	—	COMPLETED	2023-02-27	NCT04334317
Neuraly, Inc.	NLY01	—	COMPLETED	2023-02-14	NCT04154072
Hope Biosciences Research Foundation	HB-adMSCs	—	COMPLETED	2023-02-06	NCT04928287
Integrative Research Laboratories AB	Mesdopetam	—	COMPLETED	2022-12-02	NCT04435431
BioVie Inc.	NE3107	—	COMPLETED	2022-11-21	NCT05083260
SynAgile Corporation	—	—	COMPLETED	2022-07-21	NCT04778176
CuraSen Therapeutics, Inc.	clenbuterol (CST-103), nadolol (CST-107), matching placebo	—	COMPLETED	2022-07-04	NCT04739423
Anavex Life Sciences Corp.	ANAVEX2-73	—	COMPLETED	2022-05-31	NCT04575259
Supernus Pharmaceuticals, Inc.	SAGE-718	—	COMPLETED	2022-03-25	NCT04476017
Stoparkinson Healthcare Systems LLC	—	—	COMPLETED	2022-01-05	NCT04652583
Enterin Inc.	Active Investigational Treatment ENT-01	—	COMPLETED	2021-12-14	NCT03781791
Eisai Inc.	E2027	—	COMPLETED	2021-12-08	NCT04764669
Cerevance Beta, Inc.	CVN424 Low Dose	—	COMPLETED	2021-11-06	NCT04191577
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	COMPLETED	2021-09-06	NCT04867551
Annovis Bio Inc.	Posiphen	—	COMPLETED	2021-08-16	NCT04524351
Clene Nanomedicine	Gold Nanocrystals	—	COMPLETED	2021-06-07	NCT03815916
Alkahest, Inc.	AKST4290	—	COMPLETED	2021-02-11	NCT04369430
Anavex Life Sciences Corp.	High dose ANAVEX2-73	—	COMPLETED	2020-09-30	NCT03774459
Alkahest, Inc.	GRF6021	—	COMPLETED	2020-07-20	NCT03713957
Herantis Pharma Plc.	Cerebral Dopamine Neurotrophic Factor	—	COMPLETED	2020-07-08	NCT03775538
Otsuka Pharmaceutical Development & Commercialization, Inc.	SEP-363856	—	COMPLETED	2020-04-20	NCT02969369
Kyowa Kirin Co., Ltd.	KW-6356	—	COMPLETED	2020-04-15	NCT03703570
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	COMPLETED	2020-02-21	NCT03845387
Prexton Therapeutics	PXT002331 - dose 1	—	COMPLETED	2020-02-19	NCT03162874
Theranexus	THN102 Dosage A	—	COMPLETED	2019-12-20	NCT03624920
Herantis Pharma Plc.	Cerebral Dopamine Neurotrophic Factor	—	COMPLETED	2019-12-19	NCT03295786
ApoPharma	Deferiprone	Iron Chelator [EPC]	COMPLETED	2019-08-02	NCT02728843
ACADIA Pharmaceuticals Inc.	Pimavanserin	—	COMPLETED	2019-07-09	NCT03482882
Integrative Research Laboratories AB	Mesdopetam (IRL790)	—	COMPLETED	2019-06-12	NCT03368170
Impel Pharmaceuticals	—	—	COMPLETED	2019-06-11	NCT03541356
BenevolentAI Bio	BEN-2001	—	COMPLETED	2019-05-28	NCT03194217
BlackThorn Therapeutics, Inc.	BTRX-246040	—	COMPLETED	2019-04-16	NCT03608371
Dong-A ST Co., Ltd.	DA-9805 45mg	—	COMPLETED	2019-04-10	NCT03189563
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2019-03-05	NCT03292016
Edison Pharmaceuticals Inc	PTC-589	—	COMPLETED	2019-01-08	NCT02462603
Intra-Cellular Therapies, Inc.	ITI-214	—	COMPLETED	2018-09-06	NCT03257046
Jazz Pharmaceuticals	JZP-110	—	COMPLETED	2018-08	NCT03037203

Showing 100 of 174 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Highlightll Pharmaceutical (USA) LLC	HL-400	—	RECRUITING	2026-06-30	NCT06997484
Nuwacell Biotechnologies Co., Ltd.	Allogeneic dopaminergic neural precursor cell(NCR201)	—	RECRUITING	2026-07-01	NCT06978920
Vertero Therapeutics	VT-5006	—	RECRUITING	2026-09-28	NCT07310264
Serina Therapeutics	SER-252 (PEOZ-apomorphine)	—	RECRUITING	2027-01-31	NCT07422675
Innopeutics Corporation	IPS101A	—	RECRUITING	2027-10-31	NCT07371338
Eli Lilly	LY4006896	—	RECRUITING	2028-01	NCT06809400
Prevail Therapeutics	LY3962681	—	RECRUITING	2029-05-05	NCT06565195
Regeneron	ALN-SNCA	—	RECRUITING	2029-06-07	NCT07216066
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection	—	RECRUITING	2026-04-30	NCT07080775
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	RECRUITING	2026-04	NCT06608355
Gain Therapeutics, Inc.	GT-02287	—	RECRUITING	2025-11-30	NCT06732180
Longevity Biotech Australia Pty Ltd (subsidiary)	LBT-3627	—	RECRUITING	2025-10	NCT06466525
1ST Biotherapeutics, Inc.	FB418	—	RECRUITING	2024-12	NCT05995782
Brain Neurotherapy Bio, Inc.	AAV2-GDNF	—	ACTIVE NOT RECRUITING	2023-10-17	NCT04167540
H. Lundbeck A/S	Lu AF28996	—	NOT YET RECRUITING	2027-05-31	NCT07513441
Taiwan Mitochondrion Applied Technology Co., Ltd.	Aadipose-Derived Mesenchymal Stem Cells	—	NOT YET RECRUITING	2027-09-30	NCT05094011
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	Human-derived stromal cells	—	NOT YET RECRUITING	2027-10-10	NCT07232147
iCamuno Biotherapeutics Ltd.	ALC01 therapy	—	NOT YET RECRUITING	2027-12-15	NCT07212088
iRegene Therapeutics Co., Ltd.	NouvNeu001 injection	—	NOT YET RECRUITING	2028-04	NCT07550374
iCamuno Biotherapeutics Ltd.	ICA07 therapy	—	NOT YET RECRUITING	2025-12-30	NCT06821529
Luye Pharma Group Ltd.	LY03017	—	NOT YET RECRUITING	2025-10-31	NCT06793995
Luye Pharma Group Ltd.	LY03017	—	NOT YET RECRUITING	2025-10	NCT06980207
H. Lundbeck A/S	Lu AF28996	—	COMPLETED	2025-10-14	NCT04291859
Herantis Pharma Plc.	HER-096	—	COMPLETED	2025-08-14	NCT06659562
Cyto Therapeutics Pty Limited	ISC-hpNSC	—	COMPLETED	2025-06-18	NCT02452723
Neurocrine Biosciences	VY-AADC02	—	COMPLETED	2024-10-30	NCT03562494
SNLD, Ltd.	TRN501 - Dose 1	—	COMPLETED	2024-09-20	NCT06453551
Ionis Pharmaceuticals, Inc.	BIIB094	—	COMPLETED	2024-08-12	NCT03976349
Roche	RO7486967	—	COMPLETED	2024-07-18	NCT05924243
Guangzhou Henovcom Bioscience Co. Ltd.	HNC364	—	COMPLETED	2024-04-15	NCT05523570
Humanis Saglık Anonim Sirketi	Pimavanserin 34 mg	—	COMPLETED	2024-01-17	NCT06450184
Cerevel Therapeutics, LLC	Tavapadon	—	COMPLETED	2023-12-12	NCT05610189
H. Lundbeck A/S	Lu AF28996	—	COMPLETED	2023-11-21	NCT06004180
PureIMS B.V.	—	—	COMPLETED	2023-10-20	NCT06037590
Herantis Pharma Plc.	HER-096	—	COMPLETED	2023-09-29	NCT05915247
UCB Biopharma SRL	UCB7853	—	COMPLETED	2023-07-20	NCT04651153
BlueRock Therapeutics	MSK-DA01	—	COMPLETED	2023-05-18	NCT04802733
AbbVie	ABBV-951	—	COMPLETED	2023-03-17	NCT05094050
United Neuroscience Ltd.	UB-312	—	COMPLETED	2023-03-01	NCT04075318
UCB Biopharma SRL	UCB0022	—	COMPLETED	2023-02-27	NCT04867642
Mthera Pharma Co., Ltd.	MT101-5	—	COMPLETED	2023-02-23	NCT05844787
Cerevel Therapeutics, LLC	Tavapadon	—	COMPLETED	2023-01-27	NCT05581823
Five Eleven Pharma, Inc.	[18F]P17-059	—	COMPLETED	2022-12-19	NCT03903549
Sumitomo Pharma Co., Ltd.	DSP-9632P 27.5 mg	—	COMPLETED	2022-11-30	NCT05435729
Cerevance Beta, Inc.	CVN424	—	COMPLETED	2022-11-11	NCT05635461
MODAG GmbH	anle138b	—	COMPLETED	2022-11-07	NCT04685265
ABLi Therapeutics, Inc.	IkT-148009	—	COMPLETED	2022-10-30	NCT04350177
Sunshine Lake Pharma Co., Ltd.	HEC122505MsOH	—	COMPLETED	2022-01-06	NCT04625361
AstraZeneca	MEDI1341	—	COMPLETED	2022-01-05	NCT04449484
1ST Biotherapeutics, Inc.	FB-101	—	COMPLETED	2021-11-12	NCT04165837
Shijiazhuang Yiling Pharmaceutical Co. Ltd	Phenlarmide	—	COMPLETED	2021-10-29	NCT04693039
Bial R&D Investments, S.A.	Carbon-14 BIA 28-6156	—	COMPLETED	2021-10-16	NCT05220072
Jiangsu HengRui Medicine Co., Ltd.	HRG2010 Capsule, Sinemet®, Madopar®	—	COMPLETED	2021-10-07	NCT06976346
Neurocrine Biosciences	VY-AADC01	—	COMPLETED	2021-08-10	NCT03065192
H. Lundbeck A/S	Lu AF82422	—	COMPLETED	2021-07-26	NCT03611569
Cerevel Therapeutics, LLC	CVL-751	—	COMPLETED	2021-07-23	NCT04295642
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2021-05-12	NCT04630860
AstraZeneca	MEDI1341	—	COMPLETED	2021-03-31	NCT03272165
Biogen	DNL151	—	COMPLETED	2020-12-02	NCT04056689
Yiling Pharmaceutical Inc.	Phenlarmide Tablets	—	COMPLETED	2020-12-02	NCT04164121
Kyowa Kirin Co., Ltd.	KW-6356	—	COMPLETED	2020-09-05	NCT04342273
Luye Pharma Group Ltd.	LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)	—	COMPLETED	2020-08-05	NCT04384666
UCB Biopharma S.P.R.L.	UCB0599	—	COMPLETED	2020-02-19	NCT04875962
Neurocrine Biosciences	VY-AADC01	—	COMPLETED	2020-01-24	NCT01973543
Denali Therapeutics Inc.	DNL201	—	COMPLETED	2019-12-06	NCT03710707
Collaborative Medicinal Development Pty Limited	Cu(II)ATSM	—	COMPLETED	2019-11-30	NCT03204929
Kyowa Kirin Co., Ltd.	KW-6356	—	COMPLETED	2019-11-19	NCT04070495
Kyowa Kirin Co., Ltd.	KW-6356 Low Dose	—	COMPLETED	2019-10-10	NCT03830528
Kyowa Kirin Co., Ltd.	Midazolam	Benzodiazepine [EPC]	COMPLETED	2019-07-31	NCT03970798
Acorda Therapeutics	CVT-301	—	COMPLETED	2019-06-28	NCT03887884
Bial - Portela C S.A.	Ongentys	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2019-06-09	NCT03820037
AbbVie	ABBV-951	—	COMPLETED	2019-06-08	NCT03033498
Sun Pharma Advanced Research Company Limited	K0706	—	COMPLETED	2019-05-28	NCT02970019
Luye Pharma Group Ltd.	LY03003 ( Rotigotine, extended-release microspheres)	—	COMPLETED	2019-04-16	NCT04045678
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2019-03-14	NCT04629404
AbbVie	ABBV-951	—	COMPLETED	2019-03-04	NCT03374917
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2018-12-23	NCT03733561
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2018-10-31	NCT03589066
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	COMPLETED	2018-08-13	NCT03068481
Bial - Portela C S.A.	50 mg BIA 9 1067	—	COMPLETED	2018-07-24	NCT04265027
Neurocrine Biosciences	Opicapone	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2018-07-02	NCT03496870
Yiling Pharmaceutical Inc.	Finamine tablets	—	COMPLETED	2018-04-27	NCT04162275
Biogen	BIIB054	—	COMPLETED	2017-11-20	NCT02459886
Kainos Medicine Inc.	KM-819	—	COMPLETED	2017-09	NCT03022799
Bial - Portela C S.A.	Opicapone (OPC)	—	COMPLETED	2017-08-28	NCT03116295
Orion Corporation, Orion Pharma	Levodopa, carbidopa, ODM-104	—	COMPLETED	2017-07-03	NCT03140956
Bial - Portela C S.A.	[14C]-BIA 9-1067	—	COMPLETED	2017-04-27	NCT03119194
Eli Lilly	LY3154207	—	COMPLETED	2017-03-03	NCT02562768
Affiris AG	AFFITOPE® PD01A	—	COMPLETED	2017-02-28	NCT02618941
H. Lundbeck A/S	0.04 mg Lu AE04621	—	COMPLETED	2016-12	NCT02649608
Beijing Pins Medical Co., Ltd	—	—	COMPLETED	2016-12	NCT02601144
Acorda Therapeutics	CVT-301, LIP	—	COMPLETED	2016-11	NCT02807675
Prothena Biosciences Limited	PRX002	—	COMPLETED	2016-09	NCT02157714
Luye Pharma Group Ltd.	ROTIGOTINE	Nonergot Dopamine Agonist [EPC]	COMPLETED	2016-08	NCT02728947
Affiris AG	Low dose AFFITOPE® PD03A + Adjuvant	—	COMPLETED	2016-08	NCT02267434
Acorda Therapeutics	CVT-301 (Dose Level 1)	—	COMPLETED	2016-08	NCT02812394
Prexton Therapeutics	PXT002331	—	COMPLETED	2016-08	NCT02639221
NeuroDerm Ltd.	ND0612	—	COMPLETED	2016-06-30	NCT02604914
Pfizer	PF-06669571	—	COMPLETED	2016-05-13	NCT02565628
Pfizer	PF-06649751	—	COMPLETED	2016-03	NCT02224664

Novel Drugs by Company (New molecular entities)

KYOWA KIRIN 1 drug

UCB INC 1 drug

AMNEAL 1 drug

Reformulations (23 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Drug Targets

MAO-B 5 DOPA decarboxylase 4 COMT 3 Dopa-decarboxylase 2 D2 receptor 1 D3 receptor 1 D4 receptor 1 D5 receptor 1 α1D receptor 1 α2B receptor 1 α2C receptor 1 NMDAR 1 Adenosine A2A receptor 1 Dopamine receptor 1

Generic Drugs (3 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

Related Indications

Other CNS indications

View all CNS

Drug Categories:

Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
Biosimilars: BLA-approved biologics highly similar to reference products
Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology